Skip to main content
. Author manuscript; available in PMC: 2022 Mar 21.
Published in final edited form as: Br J Haematol. 2020 Nov 18;192(3):542–550. doi: 10.1111/bjh.17225

Table 2.

Categorical response rates to ibrutinib at 6 and 12 months in Waldenström macroglobulinemia patients from the learning and validation cohorts

At 6 months Learning cohort
(n=86)		 Validation cohort
(n=150)		 p-value
VGPR 8 (9%) 28 (19%) 0.18
PR 47 (55%) 78 (52%)
MR 18 (21%) 30 (20%)
NR 13 (15%) 14 (9%)
At 12 months Learning cohort
(n=76)		 Validation cohort
(n=126)		 p-value
VGPR 15 (20%) 31 (25%) 0.41
PR 41 (54%) 71 (56%)
MR 12 (16%) 18 (14%)
NR 8 (11%) 6 (5%)

VGPR: very good partial response; PR: partial response; MR: minor response; NR: no response